CDK1-IN-3

• UNSPSC Description:

  CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC50s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk1-in-3.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1CCN(C2=NN=C(CC3=CC=C(OC)C=C3)C4=C2C=CC=C4)CC1)NC5=CC=C(Cl)C(C(F)(F)F)=C5

• Molecular Weight:

  555.98

• References & Citations:

  [1]Akl L, et al. Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer. Eur J Med Chem. 2022 Aug 31;243:114704.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3032997-12-6